US Patent Issued to UROGEN PHARMA on Sept. 22 for "Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin" (New Jersey Inventor)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,740,940, issued on Sept. 22, was assigned to UROGEN PHARMA LTD. (Ra'anana, Israel).

"Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin" was invented by Sunil Raju (Princeton, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of reducing risk of bladder tumor recurrence, progression or death, or a method of increasing probability of disease-free survival at 15 months post-treatment, or a method of increasing probability of maintaining an achieved complete response for at least 15 months post-treatment comprises administering to a patient in need...